Published in Expert Opin Ther Targets on October 08, 2013
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
CRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases. Mol Psychiatry (2015) 0.83
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. PLoS One (2014) 0.78
ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. Front Aging Neurosci (2015) 0.77
The Role of 6-Gingerol on Inhibiting Amyloid β Protein-Induced Apoptosis in PC12 Cells. Rejuvenation Res (2015) 0.76
Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease. Sci Rep (2017) 0.75
Axodendritic sorting and pathological missorting of Tau is isoform specific and determined by axon initial segment architecture. J Biol Chem (2017) 0.75
Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem (2003) 2.65
Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res (2007) 2.22
Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem (2004) 1.97
Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci (2003) 1.83
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
Extracellular tau is toxic to neuronal cells. FEBS Lett (2006) 1.47
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem (2002) 1.42
Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med (2002) 1.34
Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34
GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol (2009) 1.32
Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis (2009) 1.29
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis (2003) 1.29
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem (2003) 1.19
Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett (2011) 1.17
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis (2005) 1.16
Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem (2010) 1.15
N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem (2007) 1.15
A role of MAP1B in Reelin-dependent neuronal migration. Cereb Cortex (2004) 1.13
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis (2005) 1.11
Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J (2003) 1.11
Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem (2010) 1.08
Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis (2009) 1.06
Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging (2005) 1.05
Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol (2008) 1.04
Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci (2004) 1.04
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J (2007) 1.04
Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des (2010) 1.04
MAP1B is required for Netrin 1 signaling in neuronal migration and axonal guidance. Curr Biol (2004) 1.04
A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. Arch Neurol (2005) 1.04
Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms. J Neurosci (2002) 1.03
Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging (2005) 1.02
Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement (2009) 1.02
The role of GSK3 in Alzheimer disease. Brain Res Bull (2009) 1.00
MAP1B regulates microtubule dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells. EMBO J (2013) 1.00
Deconstructing mitochondrial dysfunction in Alzheimer disease. Oxid Med Cell Longev (2013) 0.99
GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus (2010) 0.99
The influence of phospho-τ on dendritic spines of cortical pyramidal neurons in patients with Alzheimer's disease. Brain (2013) 0.99
Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann N Y Acad Sci (2005) 0.99
GSK3 inhibitors and disease. Mini Rev Med Chem (2009) 0.98
Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord (2002) 0.98
The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. FEBS Lett (2008) 0.98
Alpha-helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry (2002) 0.98
Role of MAP1B in axonal retrograde transport of mitochondria. Biochem J (2006) 0.97
Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid. Front Mol Neurosci (2011) 0.97
Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur J Biochem (2002) 0.96
Microtubule-associated protein 1B (MAP1B) is required for dendritic spine development and synaptic maturation. J Biol Chem (2011) 0.95
Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res (2003) 0.95
Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by α7 and β2* nicotinic stimulation. Toxicol Sci (2011) 0.94
Tau overexpression results in its secretion via membrane vesicles. Neurodegener Dis (2012) 0.94
Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides (2002) 0.94
Three-dimensional structure of human tubulin chaperone cofactor A. J Mol Biol (2002) 0.92
Glycogen Synthase Kinase-3 Modulates Neurite Outgrowth in Cultured Neurons: Possible Implications for Neurite Pathology in Alzheimer's Disease. J Alzheimers Dis (1999) 0.92
GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiol Aging (2003) 0.91
Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochim Biophys Acta (2004) 0.91
Characteristics of the binding of thioflavin S to tau paired helical filaments. J Alzheimers Dis (2006) 0.90
Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediators Inflamm (2013) 0.90
Microtubule-associated protein 1B interaction with tubulin tyrosine ligase contributes to the control of microtubule tyrosination. Dev Neurosci (2008) 0.89
Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis (2010) 0.89
Binding of microtubule-associated protein 1B to LIS1 affects the interaction between dynein and LIS1. Biochem J (2005) 0.89
Alzheimer disease: caspases first. Nat Rev Neurol (2010) 0.89
Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. Neurotox Res (2004) 0.88
Tangling with hypothermia. Nat Med (2004) 0.88
GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. Front Mol Neurosci (2011) 0.88
Tau aggregates and tau pathology. J Alzheimers Dis (2008) 0.88
End binding protein-1 (EB1) complements microtubule-associated protein-1B during axonogenesis. J Neurosci Res (2005) 0.87
Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J Alzheimers Dis (2009) 0.87
M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis (2004) 0.87
Neuronal microtubule-associated protein 2D is a dual a-kinase anchoring protein expressed in rat ovarian granulosa cells. J Biol Chem (2004) 0.87
Tau regulates the localization and function of End-binding proteins 1 and 3 in developing neuronal cells. J Neurochem (2015) 0.86
The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis (2005) 0.86
Further understanding of tau phosphorylation: implications for therapy. Expert Rev Neurother (2015) 0.86
Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol Neurodegener (2007) 0.86
Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. Neurosci Lett (2007) 0.86
Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. Eur J Neurosci (2002) 0.86
Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. Neurosci Lett (2004) 0.85
Tau deficiency leads to the upregulation of BAF-57, a protein involved in neuron-specific gene repression. FEBS Lett (2010) 0.85
P24, a glycogen synthase kinase 3 (GSK 3) inhibitor. Biochim Biophys Acta (2002) 0.85
Function of tau protein in adult newborn neurons. FEBS Lett (2009) 0.85
Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis (2010) 0.84
Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. Biochemistry (2004) 0.84
Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis. Hum Mol Genet (2012) 0.84
The involvement of cholinergic neurons in the spreading of tau pathology. Front Neurol (2013) 0.84
Tau protein and adult hippocampal neurogenesis. Front Neurosci (2012) 0.83
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation. J Alzheimers Dis (2002) 0.83
Tau isoform with three microtubule binding domains is a marker of new axons generated from the subgranular zone in the hippocampal dentate gyrus: implications for Alzheimer's disease. J Alzheimers Dis (2012) 0.83
Tau regulates the subcellular localization of calmodulin. Biochem Biophys Res Commun (2011) 0.82
Heme catabolism and heme oxygenase in neurodegenerative disease. Antioxid Redox Signal (2004) 0.82
Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease. J Alzheimers Dis (2009) 0.82
Altered Ca2+ dependence of synaptosomal plasma membrane Ca2+-ATPase in human brain affected by Alzheimer's disease. FASEB J (2009) 0.82
Patient-derived olfactory mucosa cells but not lung or skin fibroblasts mediate axonal regeneration of retinal ganglion neurons. Neurosci Lett (2011) 0.81
Calpain-mediated truncation of GSK-3 in post-mortem brain samples. J Neurosci Res (2009) 0.81
MDMA impairs mitochondrial neuronal trafficking in a Tau- and Mitofusin2/Drp1-dependent manner. Arch Toxicol (2014) 0.81
Expression of an altered form of tau in Sf9 insect cells results in the assembly of polymers resembling Alzheimer's paired helical filaments. Brain Res (2004) 0.81
Alterations in the nuclear architecture produced by the overexpression of tau protein in neuroblastoma cells. J Alzheimers Dis (2013) 0.81
Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. Neurobiol Aging (2011) 0.81
Selenomethionine incorporation into amyloid sequences regulates fibrillogenesis and toxicity. PLoS One (2011) 0.81
Acetylcholine receptors and tau phosphorylation. Curr Mol Med (2006) 0.81
Olfactory Ensheathing Glia: Drivers of Axonal Regeneration in the Central Nervous System? J Biomed Biotechnol (2002) 0.80